ArticleBMC cancer2021

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

Jiri Minarik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.